The Lymphoma Program has published the fall edition of the New Developments in Lymphoma Newsletter.
Please look to this space for further announcements of future newsletter issues, or sign up for advance notice of the newsletter here.
Category: Uncategorized
Dr. Ari Melnick Discusses EZH2 as a Potential Target in Diffuse Large B Cell Lymphoma
Last week Weill Cornell researcher Dr. Ari Melnick sat down with Targeted Oncology to briefly summarize the potential of EZH2 in treating diffuse large B-cell lymphoma.
New Developments in Lymphoma 